New additions to the easYmer® portfolio

We are now adding HLA-A26:01, HLA-A31:01 and HLA-A32:01 to our portfolio of loadable HLA molecules | easYmer®

The easYmer® portfolio represents, by far, the highest coverage of HLA allotypes across the regions of the world and ethnic groups. Exploitation of cellular immunity is important for future immunotherapies and general vaccine strategies (e.g covid-19) and we strive to develop reagents which enable researchers to monitor T cell responses restricted to population relevant allotypes.